BioSpace News Archive

Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the addition of Davelyn Hood, MD, to its leadership team as Director, Scientific and Patient Affairs. currently being e

The study achieved a 42% disease control rate in difficult-to-treat, second-line pancreatic cancer patients despite the absence of chemotherapy in the treatment regimen Pelareorep and pembrolizumab synergize to generate anti-cancer immune responses in patients showing disease control Clinical response was associated with increased activation of anti-cancer CD8+ T cells

Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, has initiated its pivotal clinical trial to evaluate its RheOx ™ Bronchial Rheoplasty System for the treatment of the symptoms of chronic bronchitis.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its first quarter 2021 financial results and operational highlights on Thursday, May 27, 2021 .

Ansys and Cornell University join forces to create a dynamic engineering curriculum, enabling nearly every engineering student to master simulation

Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Emily Peterson Alva , to the company’s Board of Directors (“Board”). Emily Peterson Alva is an experienced public company board member and a financial, strategic and business advisor to growth companies. A former Lazard M&A Partner with more than 15 years of banking experience

Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced a publication describing the findings of a squamous cell carcinoma (SCC) gene expression profiling (GEP) expert panel in the Journal of Drugs in Dermatology.

Newron Pharmaceuticals S.p.A. today announced that with reference to its media release of May 4, 2021, it received further Paragraph IV Notice Letters regarding the submission by a generic manufacturer of an Abbreviated New Drug Application to the U.S. Food and Drug Administration

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, is pleased to announce successful test results of two new “DehydraTECH™ 2.0" cannabidiol formulations in its second 2021 applied research and development study program, HYPER-A21-2.

Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that the latest data from HS-110, the Company’s lead product, has been accepted for poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8, 2021.